Compounded Tirzepatide (Dual GIP / GLP-1 Receptor Agonist)
Tirzepatide
Two hormones. One injection.
Unmatched results.
Tirzepatide is the next generation of metabolic medicine. While other treatments activate one pathway, Tirzepatide activates two — GIP and GLP-1 simultaneously — producing weight loss outcomes that no single-agonist therapy can match. This is precision metabolic science at its most advanced.
You're not weak.
You're fighting your own biology.
Chronic excess weight is not a behavioral failure — it is a complex hormonal disease. GIP and GLP-1 dysregulation, insulin resistance, and neurological reward system imbalances create a physiological trap that diet and exercise alone cannot escape. You need a treatment that works at the source.
Dual Hormonal Deficit
Both GIP and GLP-1 — your primary post-meal satiety hormones — are functionally impaired in obesity. A single-agonist drug addresses only half the problem. The hunger signal never fully quiets.
Stalled Weight Loss
Reached a plateau on your current medication? Previous GLP-1 therapies have a ceiling. Tirzepatide's dual mechanism breaks through where single-pathway treatments stall — producing significantly greater loss.
Severe Insulin Resistance
Type 2 diabetes, pre-diabetes, or metabolic syndrome requiring aggressive intervention. Tirzepatide's GIP receptor activity directly enhances insulin sensitivity through a separate, additive mechanism to GLP-1.
High Cardiovascular Risk
Excess visceral fat, elevated triglycerides, high blood pressure, and chronic inflammation create compounding cardiovascular danger. Every year without intervention, the risk deepens and becomes harder to reverse.
Metabolic Syndrome
Abdominal obesity, elevated fasting glucose, high triglycerides, and low HDL — occurring together, they multiply disease risk exponentially. Treating each in isolation is insufficient. You need systemic metabolic reset.
Quality of Life Collapse
Chronic fatigue, joint pain, sleep apnea, body image distress, and the daily weight of a condition medicine hasn't adequately treated. Tirzepatide produces the most significant documented improvement in obesity-related quality of life of any medication.
"Single-pathway treatments leave half your biology untreated.
Tirzepatide addresses both — and the difference is measurable, significant, transformative."
The dual-agonist that outperforms everything before it
Tirzepatide is the world's first dual GIP and GLP-1 receptor agonist — simultaneously activating two distinct incretin hormone pathways. GLP-1 suppresses appetite and slows gastric emptying. GIP enhances insulin sensitivity, improves lipid metabolism, and amplifies the fat-burning signal independently. Together, the effect is additive — and clinically unprecedented.
In head-to-head clinical trials, Tirzepatide produced an average of 20–22% body weight reduction — far exceeding the outcomes of any prior approved weight-loss therapy. Compounded by a U.S. 503A pharmacy under provider supervision, you access this technology at therapeutic, personalized doses.
Why dual-agonist changes everything
22% Average Weight Loss
The SURMOUNT-1 trial documented up to 22.5% body weight reduction — the highest ever recorded for a weekly injectable medication. GLP-1 alone achieves roughly 15%.
Superior Glucose Control
GIP receptor activation adds an independent, complementary insulin-sensitizing effect. HbA1c reductions in trials exceeded those of all previously approved diabetes therapies.
Greater Hunger Suppression
Patients on Tirzepatide report more complete silencing of food noise than those on GLP-1 monotherapy. The dual satiety signal is meaningfully stronger and more sustained.
Improved Lipid Profile
GIP receptor activity directly reduces triglycerides and raises HDL through adipose tissue modulation — an effect absent in GLP-1 monotherapy. Cardiovascular risk markers improve across the board.
What changes when both pathways activate
Tirzepatide doesn't just assist weight loss — it produces the most significant documented metabolic transformation of any injectable therapy. Here's what our patients consistently report.
Average Weight Reduction
SURMOUNT-1 trial participants on the highest dose lost an average of 22.5% of body weight over 72 weeks — nearly double what GLP-1 monotherapy achieves.
HbA1c Reduction
Fasting blood glucose and HbA1c drop dramatically, often bringing pre-diabetic and type 2 diabetic patients into normal range within months. Blood sugar stabilizes systemically.
Triglyceride Reduction
GIP receptor activation directly improves lipid metabolism. Triglycerides fall, HDL rises, and the cardiovascular risk profile shifts meaningfully toward long-term protection.
The dual molecule that rewrites metabolic limits
ILSA Health's Tirzepatide is compounded by a U.S.-regulated 503A pharmacy to exact therapeutic specifications. Every vial is traceable, potency-verified, and prescribed by a licensed provider who has reviewed your full health profile and determined your optimal titration schedule.
"Tirzepatide represents a genuine step-change — not an incremental improvement. The clinical data is unlike anything seen in metabolic medicine before."
— ILSA Health Medical TeamEverything Tirzepatide transforms
Unprecedented Fat Loss
Up to 22% body weight reduction. No medication in history has produced documented weight loss at this scale in a clinical setting.
Complete Appetite Silence
Dual satiety signaling quiets food noise more completely than any single-agonist. Patients describe the relief as profound — eating becomes neutral, not compulsive.
Blood Sugar Mastery
Dual insulin-sensitizing pathways normalize fasting glucose and post-meal spikes. Many patients achieve full remission of type 2 diabetes under supervised care.
Cardiovascular Defense
Blood pressure drops, triglycerides fall, HDL rises. Systemic inflammation resolves as visceral fat is mobilized. The cardiovascular risk profile transforms measurably.
Liver Health Restoration
Non-alcoholic fatty liver disease (NAFLD) shows dramatic improvement under Tirzepatide. Hepatic fat content reduces, liver enzymes normalize, and function improves alongside weight.
Sustained Energy
Stable blood glucose and reduced metabolic inflammation restore clean, consistent energy. No crashes, no dependency — just a body finally running efficiently.
Sleep & Mobility
Sleep apnea resolves as airway pressure reduces. Joint pain diminishes as body weight falls and inflammation clears. Movement stops being a punishment and starts being a choice.
Life Reclaimed
The largest documented improvement in obesity-related quality of life of any medication. Patients describe it as the first time their body has cooperated — and finally feeling free.
Prescription-grade.
Pharmacy prepared. Provider approved.
Compounded Tirzepatide injection from a U.S.-licensed 503A pharmacy. Prescribed only after a licensed provider reviews your complete health profile and determines your individualized dosing and titration protocol. Shipped discreetly to your door, ready to use.
Provider review included
Simple. Supervised. Delivered.
From your first assessment to your first weekly injection — the entire process is frictionless and fully supervised by licensed providers who monitor your progress and adjust your dosing throughout.
Complete Assessment
Answer our structured health questions online. Takes about 10 minutes.
Provider Reviews
A licensed U.S. provider evaluates your case and sets your titration protocol within 24–48 hours.
Pharmacy Prepares
Your 503A pharmacy compounds your Tirzepatide to your precise prescribed specifications.
Delivered to You
Shipped discreetly to your door with supplies, clear instructions, and ongoing provider support.
Before Tirzepatide.
After Tirzepatide.
Medical & Regulatory Notice
Compounded Tirzepatide is available by prescription only and requires licensed provider evaluation. Individual results vary. Compounded medications are not FDA-approved. ILSA Health does not manufacture or compound medications — all prescriptions are fulfilled by independent U.S.-licensed 503A pharmacies. Completion of an assessment does not guarantee approval or create a physician–patient relationship.
Ready to Transform
Stop settling for less.
Activate both pathways.
Complete your assessment today. A licensed provider will review your case within 24–48 hours and determine if Tirzepatide is right for you. $349/month — provider review included.
Start Your Assessment
Medical & Regulatory Notice
The health assessment offered through ILSA Health is designed for preliminary screening and educational purposes only. Completion of this questionnaire does not create a doctor–patient relationship.
All medical services, including clinical evaluations, treatment plans, and prescription decisions, are provided exclusively by independent U.S.-licensed healthcare providers. Providers exercise full medical judgment and determine eligibility based on individual clinical assessment and applicable state regulations.
If approved, prescriptions are dispensed by U.S.-based 503A compounding pharmacies that are registered with the FDA and operate in compliance with United States Pharmacopeia standards. Compounded medications are not FDA-approved and have not undergone FDA evaluation for safety, effectiveness, or manufacturing consistency.
Individual responses to treatment vary. No specific results are guaranteed.
ILSA Health does not manufacture, compound, or directly dispense medications. Product appearance, packaging, and labeling may vary from images shown on this website.
All trademarks and product names are the property of their respective owners.
GET SUPPORT
Email: [email protected]
Phone: 754 227 9 227
Phone: 754 227 9 227
1600 S Dixie HWY, Suite 108,
Boca Raton FL 33432
QUICK LINKS
Home
Home
Home
Home
Home
Home
TREATMENTS:
Personalized Tirzepatide
Personalized Semaglutide
FAQ
MEDICAL:
Tirzepatide Safety Information
Semaglutide Safety Information
PATIENTS:
Login
Get Started
Referral Program
LEGAL:
© Ilsa Health - 2026 All Rights Reserved
Clinic Designed By: Med Clinic Auhtority